IL159998A0 - Autologous t-cell vaccines materials and methods - Google Patents

Autologous t-cell vaccines materials and methods

Info

Publication number
IL159998A0
IL159998A0 IL15999802A IL15999802A IL159998A0 IL 159998 A0 IL159998 A0 IL 159998A0 IL 15999802 A IL15999802 A IL 15999802A IL 15999802 A IL15999802 A IL 15999802A IL 159998 A0 IL159998 A0 IL 159998A0
Authority
IL
Israel
Prior art keywords
methods
autologous
cell vaccines
vaccines materials
materials
Prior art date
Application number
IL15999802A
Other languages
English (en)
Original Assignee
Baylor College Medicine
Opexa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine, Opexa Pharmaceuticals Inc filed Critical Baylor College Medicine
Publication of IL159998A0 publication Critical patent/IL159998A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15999802A 2001-09-14 2002-09-12 Autologous t-cell vaccines materials and methods IL159998A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/952,532 US7658926B2 (en) 2001-09-14 2001-09-14 Autologous T-cell vaccines materials and methods
PCT/US2002/028874 WO2003024393A2 (en) 2001-09-14 2002-09-12 Autologous t-cell vaccines materials and method

Publications (1)

Publication Number Publication Date
IL159998A0 true IL159998A0 (en) 2004-06-20

Family

ID=25492995

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15999802A IL159998A0 (en) 2001-09-14 2002-09-12 Autologous t-cell vaccines materials and methods
IL196900A IL196900A (en) 2001-09-14 2009-02-04 Autologous T cell vaccine compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL196900A IL196900A (en) 2001-09-14 2009-02-04 Autologous T cell vaccine compositions

Country Status (21)

Country Link
US (2) US7658926B2 (da)
EP (3) EP1416956B1 (da)
JP (5) JP2005502721A (da)
KR (1) KR20040066787A (da)
CN (2) CN100346824C (da)
AT (1) ATE395076T1 (da)
AU (1) AU2002339914B2 (da)
BR (1) BR0212504A (da)
CA (1) CA2459969C (da)
DE (1) DE60226612D1 (da)
DK (2) DK2335720T3 (da)
ES (2) ES2418529T3 (da)
HU (1) HUP0401519A3 (da)
IL (2) IL159998A0 (da)
MX (1) MXPA04001862A (da)
NZ (1) NZ530762A (da)
PL (1) PL210442B1 (da)
PT (2) PT1416956E (da)
RU (1) RU2302257C2 (da)
WO (1) WO2003024393A2 (da)
ZA (1) ZA200401502B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009448A1 (en) * 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US7744893B2 (en) * 2002-06-05 2010-06-29 Baylor College Of Medicine T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
US7695713B2 (en) * 2002-08-08 2010-04-13 Baylor College Of Medicine Isolation and identification of T cells
EP1583823A4 (en) * 2002-12-31 2006-02-22 Baylor College Medicine ISOLATION AND IDENTIFICATION OF CROSS-REACTIVE T CELLS
EP1677821B1 (en) * 2003-10-17 2013-02-27 Baylor College Of Medicine A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis
AU2007247869B2 (en) * 2006-05-05 2013-11-21 Opexa Therapeutics T-cell vaccine
RU2339385C1 (ru) * 2007-04-02 2008-11-27 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения ревматоидного артрита
PL2318020T3 (pl) * 2008-06-30 2016-02-29 Univ Heidelberg Immunosupresyjne komórki krwi i sposób ich wytwarzania
RU2393218C1 (ru) * 2009-01-30 2010-06-27 Федеральное государственное учреждение "Центральный научно-исследовательский институт травматологии и ортопедии имени Н.Н. Приорова Росмедтехнологий" Среда для выращивания культуры аутологичных лимфоцитов
US20170246272A1 (en) * 2014-09-05 2017-08-31 Opexa Therapeutics, Inc. Compositions and methods for treating b cell mediated autoimmune disorders
CN109125717B (zh) * 2017-09-08 2022-02-22 江苏苏博生物医学股份有限公司 一种治疗慢性病的自体全细胞疫苗配方及其制备方法
WO2019133793A1 (en) 2017-12-29 2019-07-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions and methods for treating autoimmune disease

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4550086A (en) 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
IL69686A (en) 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4608365A (en) 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
US4677061A (en) 1984-10-19 1987-06-30 Genetic Systems Corporation T-cell lymphocyte subset monitoring of immunologic disease
US4897389A (en) 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
US4898856A (en) 1984-10-29 1990-02-06 Chaovanee Aroonsakul Method for treating central nervous system diseases
US4902680A (en) 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
US4898857A (en) 1984-10-29 1990-02-06 Chaovanee Aroonsakul Treating control nervous system diseases
CA1296622C (en) 1986-08-12 1992-03-03 Jeffrey E. Anderson Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
US5242687A (en) 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5837246A (en) 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6007815A (en) 1989-03-21 1999-12-28 The Immune Response Corporation Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6207645B1 (en) 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5861164A (en) 1989-03-21 1999-01-19 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5298396A (en) 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
IL97709A (en) 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
WO1992001044A1 (en) 1990-07-06 1992-01-23 Allergene, Inc. Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US6083503A (en) 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
US5480895A (en) 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5298386A (en) * 1992-06-09 1994-03-29 Eastman Kodak Company In-line solvent incorporation for amorphous particle dispersions
US5545716A (en) 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
EP0688223A4 (en) 1993-03-12 1998-05-13 Cellcor Inc -i (IN VITRO) 'ASSAY' FOR MEASURING THE DEGREE OF ACTIVATION OF IMMUNE CELLS
WO1994022451A1 (en) 1993-04-07 1994-10-13 Oklahoma Medical Research Foundation Selective regulation of b lymphocyte precursors by hormones
IL108926A0 (en) 1993-05-14 1994-06-24 L Willems Instituut Dr Human t cell monoclone, process for its production and its use for the treatment and diagnosis of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
US5552300A (en) 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6410518B1 (en) * 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5674487A (en) 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
US5723503A (en) 1994-09-28 1998-03-03 Thomas Jefferson University Biological treatment for rheumatoid arthritis
US6033661A (en) 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
US6096314A (en) 1994-10-07 2000-08-01 Yeda Research And Development Co. Ltd. Peptides and pharmaceutical compositions comprising them
FR2727117A1 (fr) 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
DE69525544T2 (de) 1994-11-18 2002-08-22 Neurocrine Biosciences, Inc. Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5874531A (en) 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5869057A (en) 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
SE9502921D0 (sv) 1995-08-23 1995-08-23 Astra Ab New compounds
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5716946A (en) 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5849886A (en) 1996-07-10 1998-12-15 Oy Aboatech Ab Extraction of myelin basic protein
US20010031253A1 (en) 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
DE69718029T2 (de) 1996-10-11 2003-10-16 The Regents Of The University Of California, Oakland Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6054292A (en) 1997-07-18 2000-04-25 Incyte Pharmaceuticals, Inc. T-cell receptor protein
US20020009448A1 (en) 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO2000014116A1 (en) 1998-09-04 2000-03-16 Baylor College Of Medicine T cell peptides as therapeutics for immune-related disease
EP1159457B1 (en) 1999-02-23 2010-11-03 Baylor College Of Medicine T cell receptor vbeta - dbeta - jbeta) sequence and methods for its detection
US6187750B1 (en) 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
US6746670B2 (en) 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
JP2004506743A (ja) 2000-08-22 2004-03-04 ベイラー　カレッジ　オブ　メディシン Ｔ細胞レセプターＶβ−Ｄβ−Ｊβ配列およびその検出方法
US7658926B2 (en) 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
EP1444330A1 (en) 2001-11-07 2004-08-11 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
DE10224223A1 (de) * 2002-05-31 2003-12-11 Mann & Hummel Filter Filterelement, insbesondere zur Flüssigkeitsfilterung aus einem Gasstrom

Also Published As

Publication number Publication date
ES2306792T3 (es) 2008-11-16
CN101229370A (zh) 2008-07-30
PL367306A1 (pl) 2005-02-21
AU2002339914B2 (en) 2005-03-24
DK2335720T3 (da) 2013-07-08
JP2015017129A (ja) 2015-01-29
HUP0401519A2 (hu) 2004-11-29
EP1416956A2 (en) 2004-05-12
CN101229370B (zh) 2015-09-02
DE60226612D1 (de) 2008-06-26
HK1071698A1 (zh) 2005-07-29
WO2003024393A2 (en) 2003-03-27
NZ530762A (en) 2005-10-28
CA2459969C (en) 2014-12-02
IL196900A0 (en) 2011-07-31
EP1416956B1 (en) 2008-05-14
ATE395076T1 (de) 2008-05-15
WO2003024393A3 (en) 2003-11-06
RU2302257C2 (ru) 2007-07-10
CN100346824C (zh) 2007-11-07
US20050186192A1 (en) 2005-08-25
CA2459969A1 (en) 2003-03-27
ZA200401502B (en) 2005-01-26
US20030091578A1 (en) 2003-05-15
EP1416956A4 (en) 2004-10-13
RU2004103626A (ru) 2005-03-27
JP2007254492A (ja) 2007-10-04
MXPA04001862A (es) 2005-03-07
IL196900A (en) 2015-03-31
ES2418529T3 (es) 2013-08-14
EP2335720A1 (en) 2011-06-22
DK1416956T3 (da) 2008-09-01
EP2335720B1 (en) 2013-04-03
HUP0401519A3 (en) 2009-04-28
EP1946767B1 (en) 2013-12-04
PT1416956E (pt) 2008-08-26
US7658926B2 (en) 2010-02-09
EP1946767A3 (en) 2008-07-30
CN1553812A (zh) 2004-12-08
JP2011168618A (ja) 2011-09-01
JP2016188238A (ja) 2016-11-04
BR0212504A (pt) 2004-08-24
JP2005502721A (ja) 2005-01-27
JP4889581B2 (ja) 2012-03-07
KR20040066787A (ko) 2004-07-27
PT2335720E (pt) 2013-07-08
PL210442B1 (pl) 2012-01-31
EP1946767A2 (en) 2008-07-23

Similar Documents

Publication Publication Date Title
IL196900A0 (en) Autologous t-cell vaccines compositions
AU5090401A (en) Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis
IL150223A (en) Lipopeptides and pharmaceuticals containing them
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
DE60118558D1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
WO2001021766A8 (en) Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells
HUP0300369A2 (hu) Többértékű antitestek és alkalmazásuk
WO2004015070A3 (en) Isolation and identification of t cells
DE69635406D1 (de) Chemokinrezeptor 88c sowie dessen antikörper
BG105028A (en) Bridged indenopyrrolocarbazoles
ID28432A (id) Senyawa-senyawa baru
HUP9901788A3 (en) Enhanced production of taxanes by cell cultures of taxus species
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
EP0642507A4 (en) Catalytic antibodies against cocaine and methods of using and producing same.
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
AU2826801A (en) Surface modified supporting materials for binding biological materials, method for the production and use thereof
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
DE60201892D1 (en) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
DE60309847D1 (de) Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
DE69333351D1 (de) Rekombinante lipase aus hundemagen und pharmazeutische zusammensetzungen
IL159122A (en) Allylmercaptocaptopril compounds and uses thereof
SI1200592T1 (sl) Sesalski citokini; sorodni reagenti
MXPA04004262A (es) Delta-1-pirrolinas.
GB9919732D0 (en) Trehalose producing cells as vaccines
PT102695A (pt) Processo para a preparacao de oligossacaridos com actividade anti-ulcerativa e sua utilizacao para apreparacao de medicamentos

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees